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Background. It is urgent to find alternative agents due to increasing failure rate of Helicobacter pylori (H. pylori) eradication. The
study surveyed the long-term effect of silver nanoparticles (AgNP) on H. pylori based on Mongolian gerbil’s model.Materials and
Methods. Fifty gerbils were randomly allocated to six groups (A–F). Group (Gr) A: the gerbils were fed with broth; Gr B and D: the
gerbils were fed with AgNP/clay complex (0.1% of weight); Gr C and E: the gerbils were fed with AgNP/clay complex(1% of weight);
and Gr D, E, and F: the gerbils were inoculated withH. pylori. At the 20th experimental week, the gerbils were sacrificed. Histology
was evaluated according to the classification of the Sydney system. 𝑃 < 0.05 was considered to be statistically significant. Results.
The AgNP/clay has more obvious inhibitory effect on H. pylori in vitro. There was a trend of higher concentrations of AgNP with
stronger inhibitory effect onH. pylori growth (𝑃 = 0.071). There were no significant differences of inflammation among groups D,
E, and F (𝑃 = 0.688).Conclusion. AgNP/clay would be a potential and safe agent for inhibiting H. pylori. It should be helpful for
eradication of H. pylori infection.
1. Introduction
Helicobacter pylori (H. pylori) infection is an important factor
of many gastrointestinal diseases such as chronic gastritis,
peptic ulcer, and gastric cancer. Eradication of H. pylori is
the most important strategy for treatment of these diseases.
However, the failure rate of currently used first-line therapies
has increased up to 30% [1–4]. Therefore, there is an urgent
need to find alternative agents to improve the efficacy.
The potential side effects of bismuth decrease the com-
pliance of second-line eradication therapies. For the conven-
tional antimicrobial treatments, some metals including silver
in large quantities are applied to control skin infection [5], so
previous studies applied silver to be the alternative treatment
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for gastrointestinal symptoms and infections (including H.
pylori) [6]. Besides this, silver compounds have been used as
antiulcer agents [7]. BecauseH. pylori is a major peptic-ulcer
cause, it is logical that the antiulcer activity of silver might be
related to its effects on H. pylori.
Currently, metal-based nanopreparations have become
more and more important in their applications in various
fields including antimicrobial abilities [8–14]. The synthesis
of silver nanoparticles (AgNP) has aroused more interest
because of the broad applications including wound dressings
and medical devices [10, 11, 13, 15, 16]. The possible mecha-
nism of action of metallic agents is the inhibition ofH. pylori
urease [17–19]. However, previous studies weremostly in vivo
studies, so we need an ideal animal model to survey the long-
term effects of AgNP exposure on human physiology and
H. pylori. Watanabe et al. [20] demonstrated that H. pylori
infection could induce well-differentiated adenocarcinoma
based on a Mongolian gerbil’s model. The Mongolian gerbils
provide a suitable experimental animal model, so the aim of
our study was to survey the long-term effect of AgNP on H.
pylori based on a Mongolian gerbil’s model.
2. Materials and Methods
Experiments were performed according to the experimental
guidelines of the Ethics Committee of Kaohsiung Medical
University Laboratory Animal Center.
2.1. Animals and Housing. Eight-week-old gerbils with body
weight of 30–40 gm were purchased from the Kaohsiung
Medical University Experimental Animals Center, Kaohsi-
ung, Taiwan. In usual time, 4 to 5 gerbils per cagewere housed
and maintained under standard laboratory conditions (room
temperature, 23∘C∼26∘C; relative humidity, 55%∼65%; 12/12-
hour light/dark cycle) with free access to a commercial rodent
diet and tap water.
2.2. Synthesis of AgNP/Clay Nanohybrid. The AgNP/clay
complex was prepared via the reduction of silver ions in
water according to the procedures reported previously [21].
In a typical experimental procedure, the lucentite SWN clay
slurry (30 g, 1 wt% in water; DEUCHEM Co., Taiwan) was
prepared by swelling in deionized water at 80∘C and the
AgNO
3
solution (3.4 g, 1.0 wt% in water; J.T. Baker, USA)
was then added to this slurry. The reducing agent was
added to the AgNO
3
/clay solution and the mixture was
vigorously stirred and heated at 80∘C for 3 h. During the
process, a color change was observed from yellowish to
deep red, indicating the reduction of Ag+ to Ag0. The UV
absorption at 420 cm−1 was observed using a UV-mini 1240
spectroscope. The Ag particle size on clay was measured
with a field emission scanning electron microscope (FE-
SEM, Zeiss EM 902A) at 80 kV. The d spacing was analyzed
using a Shimadzu SD-D1 X-ray diffractometer with a Cu
target (𝛾 = 1.5405 A˚) at a generator voltage of 35 kV, a
generator current of 30mA, and a scanning rate of 2∘/min.
The inorganic fraction was determined by decomposing the
composites at temperatures up to 900∘C. The concentration
of dissolved Ag+ in solution was determined with induc-
tively coupled plasmamass spectrometry (ICP-MS) provided
in National Sun Yat-Senlinebreak University and National
Tsing Hua University of Taiwan.The supernatant of a 0.1 wt%
AgNP/clay sample in solution was collected after centrifuga-
tion at 16,000×g for 30min. ICP-MS analysis showed the Ag+
concentration to be in a range of 139.33 ± 16.04 ppb. After
adding 3%HNO
3
to the supernatant to convert the freeAg0 to
Ag+, the concentration increased to 155.33 ± 34.53 ppb. [15].
2.3. Dose Escalation of AgNP. Part I: the optimal concentra-
tion of the antibacterial activity of AgNP/clay: AgNP/clay
(0.06%, 0.08%, 0.1%, 0.2%, and 0.3% of weight) was added
into the Brucella broth containing bacteria 1 × 103 CFU/mL
and then they were incubated at 37∘C. The incubation time
was 12 hours. Then 100 𝜇L of these cultured broths were
spread on CDC Anaerobe 5% Sheep Blood Agar (BD, USA)
and incubated at 37∘C with 5% O
2
conditions. The colony
numbers were counted after 48 hours of incubation. Part II:
the time course of the antibacterial activity of AgNP/clay:
AgNP/clay (0.01%, 0.05%, and 0.1% of weight) was added into
the Brucella broth containing bacteria 1 × 103 CFU/mL and
then they were incubated at 37∘C. The incubation time was
0, 0.5, 1, 2, 4, 12, and 24 hours, irrespectively. Then 100 𝜇L of
these cultured brothswas spread onCDCAnaerobe 5%Sheep
Blood Agar (BD, USA) and incubated at 37∘C with 5% O
2
conditions. The colony numbers were counted after 48 hours
of incubation.
2.4. H. pylori Inoculation. The gerbils were randomly allo-
cated to six groups according to a randomized number (A–
F): group A: the gerbils were fed with broth only; group B:
the gerbils were fed with AgNP/clay complex (0.1% of weight)
in the 8th to 20th week; group C: the gerbils were fed with
AgNP/clay complex (1% of weight) in the 8th to 20th week;
group D: the gerbils were inoculated with H. pylori [CagA
(+)/VacA (+)] during the 1st to 4th week and then they were
fed with AgNP/clay complex (0.1% of weight) in the 8th to
20th week; group E: the gerbils were inoculated withH. pylori
[CagA (+)/VacA (+)] during the 1st to 4th week and then they
were fed with AgNP/clay complex (1% of weight) in the 8th to
20th week; group F: the gerbils were inoculated withH. pylori
[CagA (+)/VacA (+)] during the 1st to 4th week. At the end
of the 20th experimental week, the animals were fasted for 24
hours before being sacrificed (Figure 1).
2.5. Histological Evaluation of the Gastric Mucosa in Gerbils.
Samples of the gastric mucosa were excised from each gerbil
stomach for the assessment of the presence of H. pylori and
gastric inflammation using Giemsa and hematoxylin-eosin
(HE) staining for histological examination, respectively. The
sampleswere fixed in 10%buffered formalin and embedded in
paraffin [II-34]. The paraffin sections were cut at a thickness
of 5mm and stained. Two experienced pathologists, blinded
to the treatment given, performed histological examinations.
Histological features of mucosal inflammation and intestinal
metaplasia were evaluated for each specimen under a light
microscope according to the classification of the Sydney
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Figure 1: The timing of AgNP/clay and H. pylori given. Group (Gr)
A: the gerbils were fed with broth only. Gr B and D: the gerbils were
fed with AgNP/clay (0.1% of weight) in the 8th to 20th week. Gr C
and E: the gerbils were fed with AgNP/clay (1% of weight) in the 8th
to 20th week. Gr D, E, and F: the gerbils were inoculated with H.
pylori [CagA (+)/VacA (+)] in the 1st to 4th week. At the end of the
20th experimental week, the animals were fasted for 24 hours before
being sacrificed.
system. The degree of inflammatory cell infiltration and the
area of intestinalmetaplasiawere scored as follows: 0, normal;
1, mild; 2, moderate; 3, marked.
2.6. Statistical Analyses. We analyzed the collected data using
the statistical software package SPSS. Kruskal-Wallis test was
used for comparing histological change of mucosa. 𝑃 < 0.05
was considered to be statistically significant.
3. Results
The inhibitory effects of different materials on H. pylori
were surveyed.The results revealed that AgNP/clay has more
obvious inhibitory effect on H. pylori. This inhibitory effect
became more obvious when the concentration of AgNP/clay
was more than 0.08% of weight. However, the clay did not
show any inhibitory effect in any concentration. The AgNP
had mild inhibitory effect only at high concentration (0.3%
of weight) (Figure 2).
We surveyed the reaction time of inhibiting H. pylori
in different concentrations of AgNP/clay. We found that
the higher the concentration of AgNP/clay, the shorter the
reaction time. In concentration of 0.1% weight of AgNP/clay,
H. pylori would be completely inhibited since the 12th hour
and this effect would persist up to the 24th hour (Figure 3). So
the optimal frequency of feeding AgNP/clay might be daily.
Fifty gerbils were used in this study. The numbers of
gerbils in each group were 6 (Gr A), 6 (Gr B), 6 (Gr C),
11 (Gr D), 15 (Gr E), and 6 (Gr F), respectively. The study
design is shown in Figure 1. In our study, all gerbils were alive
till the end of this experiment, and there was no significant
difference in the survival rates among the various groups. On
the 13th week, the positive rates of H. pylori were all 100% in
groups D, E, and F.
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Figure 2: The inhibitory effects of different materials on H. pylori
were surveyed. The results revealed that AgNP/clay has more obvi-
ous inhibitory effect on H. pylori (concentration more than 0.08%
of weight). However, clay did not have the inhibitory effect and the
AgNP had mild inhibitory effect only in high concentrations. H.
pylori: Helicobacter pylori; AgNP: silver nanoparticles.
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Figure 3: We surveyed the reaction time of inhibiting H. pylori in
different concentrations of AgNP/clay. We found that the higher
the concentration, the shorter the reaction time. H. pylori could be
completely inhibited within 12 hours in a concentration of 0.1% of
weight. H. pylori: Helicobacter pylori; AgNP: silver nanoparticles.
We surveyed the densities ofH. pylori in groups D, E, and
F. We wanted to survey the inhibitory effect of AgNP on H.
pylori.The average densities ofH. pylori (according to Sydney
classification)were 1.45±0.52, 1.27±0.70, and 1.83±0.41 inGr
D, E, and F, respectively. It did not show significant difference
between the three groups (𝑃 = 0.071); however, we found the
trend that higher concentrations of AgNP had stronger effect
on inhibiting H. pylori (Figures 4 and 6).
The possible toxic effect of AgNP on gastric mucosa and
its interaction with H. pylori were also surveyed. We showed
the severity of inflammation of gerbil’s mucosa according to
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Figure 4: The status of H. pylori densities in groups D, E, and F
is shown. Group F had obviously higher proportion of moderate
and high H. pylori densities. It disclosed that AgNP/clay had an
inhibitory effect on H. pylori. H. pylori: Helicobacter pylori; AgNP:
silver nanoparticles.
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Figure 5: The inflammatory severities of gerbils’ stomach in differ-
ent groups are shown. All gerbils in groups A, B, and C showedmild
inflammation only. The proportion of obvious inflammation was
more than mild inflammation in groups D, E, and F. The difference
was the most obvious in group F. However, there was no significant
difference among these groups.
the Sydney classification. There was no sign of inflammation
noted in group A. However, all gerbils in groups B and
C had mild monocyte infiltration but without neutrophil
infiltration. The results of the inflammatory scores were 0 ±
0 (Gr A), 1.00 ± 0 (Gr B), 1.00 ± 0 (Gr C), 4.27 ± 1.10
(Gr D), 4.20 ± 1.82 (Gr E), and 4.83 ± 1.17 (Gr F). The
proportions of moderate to severe inflammation were 0%
(0/6), 0% (0/6), 0% (0/6), 54.5% (6/11), 53.3% (8/15), and
66.7% (4/6) in groups A, B, C, D, E, and F (Figures 5 and
6). The results revealed that AgNP alone did not have an
acute toxic effect on gerbil’s gastric mucosa. Besides these,
there were no significant differences of inflammation among
groups D, E, and F (𝑃 = 0.688).
4. Discussion
The approaches to overcoming drug resistance include
increasing the dosage and treatment duration of drugs and
using multiple drugs or pretreatment with agents to reduce
bacterial load. The agents used to decrease H. pylori load
include probiotics, bismuth, or some herbs. Our study was
designed to survey whether AgNP could reduce theH. pylori
load in gerbils.
To the best of our understanding, the present investi-
gation can be considered to be the first report of the anti-
H. pylori activity of silver nanoparticles based on a gerbil
model. A previous study showed that silver nanoparticlesmay
have the effect of inhibiting urease activity of H. pylori [19].
However, these previous studieswere under the evidence of in
vitro studies.We chose 13 weeks as the intervention’s duration
according to our previous preliminary data (not published)
of Mongolian gerbil’s model. We found that H. pylori would
induce obvious inflammation since this time point. So we
expected that there might be obvious difference in different
groups at this time point.
According to our results, AgNP could not completely
inhibit the growth of H. pylori neither in low nor high
concentrations of AgNP. But AgNP showed the potential
effect of decreasing densities of H. pylori and also had dose-
dependent response. This supported the notion that AgNP
might be a bacteriostatic agent for H. pylori. Our results
supported the finding of a previous study [19]. The effect of
inhibition was directly related to AgNP/clay itself but not free
silver ion in solution, because the synthesized AgNP/clay was
nearly free of Ag+ leaching from the nanohybrid, even after a
storage period of six months at room temperature.
Multiple investigations have been performed to show the
antibacterial activity of metals andmetals chelated with some
ligands against H. pylori [22, 23]. According to a previous
report, the charged clay could trap bacteria and the close
interfacial interaction between bacteria and AgNP plays a
cardinal role in inhibiting bacteria [15].The contact and inter-
action between the AgNP/clay and the cell wall of bacterium
is important to trigger a cytotoxic signal; unfortunately, H.
pyloriwas colonizedwithin the gel layer of gastricmucosa and
we thought that the gel layer might interfere with the contact
between H. pylori and AgNP/clay. This should be one of the
reasons in whichH. pylori was not inhibited obviously in our
gerbil’s model.
A previous study found that under anaerobic conditions,
newly synthesized AgNP/clay still enabled suppression of
cell growth as efficiently as under aerobic conditions [15].
So its effect would not be influenced by the microanaerobic
environment in which H. pylori lives. Another possible
challenge is the acidic environment in the stomach; one study
revealed that the bactericidal effect would diminish in an
acidic environment [24]. This might be one of the reasons
that AgNP/clay only had bacteriostatic effect in the gerbil’s
stomach.
The bacterial load is an important factor for eradication
of H. pylori. Previous studies demonstrated that decreasing
the amount of H. pylori would increase the success rate of
eradication [25]. They usually used bismuth as the agent for
BioMed Research International 5
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Figure 6: Histological changes of different groups are shown (H&E stain 1000x). We show the status ofH. pylori density in right field and the
status of inflammation in left field. There is no obvious inflammatory cells infiltration in groups A, B, and C, but obvious inflammatory cells
infiltration was noted in groups D, E, and F. The densities of H. pylori were higher in group F.
inhibiting H. pylori, but the side effects of bismuth were
obvious andwould decrease the compliance and success rates.
Another method might use more complex regimens, such
as sequential therapies, to achieve successful eradication by
lower bacterial load. In our study, we found that AgNP had
the effect of inhibiting H. pylori. Our study might provide
another reliable way to help us eradicate H. pylori.
A previous study in vitro demonstrated that urease
inhibitory activity increased linearly with increased concen-
tration of AgNP. So we tried two different doses of AgNP/clay
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(1% weight versus 0.1% weight) to survey the dose-dependent
response. On the other hand, the possible toxic effect of
AgNP was an important concern of this study. Many studies
have revealed AgNP to have mild toxicity against several
cell lines and the possible mechanism of these toxic effects
is under survey [26–28], so our study also surveyed the
toxic effect on gastric mucosa. In our results, no obvious
mucosal damage was found in groups B and C. According
to previous study [6], the paper clearly demonstrated that
fed silver nanoparticles were not absorbed by animal. In our
study, we did not find any evidence about AgNP absorbed by
gastrointestinal mucosa. However, further survey and longer
observation period would be needed for application of AgNP
in human.
There were some limitations of our study. One was the
duration of feeding AgNP. To our best knowledge, there is
no previous similar design reported in Mongolian gerbil’s
model, so we did not know the optimal intervention period.
Itmight need longer therapeutic period for obtaining obvious
inhibitory effect. Another limitationwas the unequal number
of gerbils used in these groups. However, we used more
gerbils in groups D and E (fed both H. pylori and AgNP).
The number per group of gerbils used in previous studies was
around six to ten, so the number of gerbils used in our study
groups A, B, C, and F was enough for analysis. Besides this,
we kept feeding gerbils during the experiment and the various
ions in the food might have interaction with AgNP/clay. So
the effect of AgNP/clay onH. pyloriwas possibly diminished.
In summary, our study showed that AgNP/clay would
be a potential and safe agent for decreasing the amount of
H. pylori. It should be helpful for eradication of H. pylori
infection and needs further survey on the method given.
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